UK markets close in 34 minutes

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
48.30+2.33 (+5.07%)
As of 10:56AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.09B
Enterprise value 2.17B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)33.06
Price/book (mrq)4.32
Enterprise value/revenue 23.60
Enterprise value/EBITDA -7.23

Trading information

Stock price history

Beta (5Y monthly) 1.68
52-week change 3-23.73%
S&P500 52-week change 3-8.00%
52-week high 380.00
52-week low 327.77
50-day moving average 342.94
200-day moving average 346.49

Share statistics

Avg vol (3-month) 3815.66k
Avg vol (10-day) 3665.04k
Shares outstanding 570.47M
Implied shares outstanding 6N/A
Float 858.15M
% held by insiders 11.81%
% held by institutions 187.32%
Shares short (12 Jan 2023) 413.01M
Short ratio (12 Jan 2023) 414.78
Short % of float (12 Jan 2023) 421.25%
Short % of shares outstanding (12 Jan 2023) 418.46%
Shares short (prior month 14 Dec 2022) 411.74M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-171.86%

Management effectiveness

Return on assets (ttm)-7.88%
Return on equity (ttm)-40.23%

Income statement

Revenue (ttm)91.95M
Revenue per share (ttm)1.33
Quarterly revenue growth (yoy)1,970.60%
Gross profit (ttm)-180.29M
EBITDA -145.19M
Net income avi to common (ttm)-315.45M
Diluted EPS (ttm)-3.59
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.09B
Total cash per share (mrq)15.9
Total debt (mrq)178.5M
Total debt/equity (mrq)24.98
Current ratio (mrq)4.64
Book value per share (mrq)10.38

Cash flow statement

Operating cash flow (ttm)93.55M
Levered free cash flow (ttm)54.13M